Akeega (abiraterone acetate and niraparib) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Janssen Inc. Akeega (abiraterone acetate and niraparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078864.PDF. Revised March 2025. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
AKEEGA (niraparib and abiraterone acetate) is indicated with prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)